DelveInsight’s “Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Beta Thalassemia, historical and forecasted epidemiology as well as the Beta Thalassemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Beta Thalassemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Beta Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Beta Thalassemia Market Insights
Beta Thalassemia Overview
Beta thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.
Some of the key facts of the Beta Thalassemia Market Report:
- The Beta Thalassemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- According to a report from the World Health Organization (2020), more than 65,000 infants born with β-thalassemia each year, of whom about 25,500 have transfusion-dependent β-thalassemia
- According to Kattamis et al. (2020), β-thalassemia has been more common in certain regions of the world such as the Mediterranean, Middle East, and Southeast Asia
- Key Beta Thalassemia Companies: CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, bluebird bio, BRL Medicine, Celgene, and others.
- Key Beta Thalassemia Therapies: SLN124, Sapablursen, Mitapivat, and others
Get a Free sample for the Beta Thalassemia Market Report -
https://www.delveinsight.com/sample-request/beta-thalassemia-market-forecast
Key benefits of the Beta Thalassemia Market report:
- Beta Thalassemia market report covers a descriptive overview and comprehensive insight of the Beta Thalassemia Epidemiology and Beta Thalassemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Beta Thalassemia market report provides insights on the current and emerging therapies.
- Beta Thalassemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Beta Thalassemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Beta Thalassemia market.
Download the report to understand which factors are driving Beta Thalassemia epidemiology trends @ Beta Thalassemia Epidemiological Insights
Beta Thalassemia Market
The dynamics of the Beta Thalassemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
Beta Thalassemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Beta Thalassemia Epidemiology Segmentation:
The Beta Thalassemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Beta Thalassemia
- Prevalent Cases of Beta Thalassemia by severity
- Gender-specific Prevalence of Beta Thalassemia
- Diagnosed Cases of Episodic and Chronic Beta Thalassemia
Beta Thalassemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Beta Thalassemia market or expected to get launched during the study period. The analysis covers Beta Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Beta Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major Beta Thalassemia market share @ Beta Thalassemia market forecast
Beta Thalassemia Therapies and Key Companies
- SLN124: Silence Therapeutics
- Sapablursen: IonisPharmaceutical
- Mitapivat: Agios Pharmaceuticals
Beta Thalassemia Market Strengths
- Increasing investment in R&D among the major players involved in cutting edge drug development technology
- Robust pipeline with well-designed, randomized controlled trials and rising collaborations and agreements between developers
- Increasing prevalence and awareness of beta thalassemia
- Better diagnostic techniques
Scope of the Beta Thalassemia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Beta Thalassemia Companies: CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, bluebird bio, BRL Medicine, Celgene, and others.
- Key Beta Thalassemia Therapies: SLN124, Sapablursen, Mitapivat, and others
- Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies
- Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Beta Thalassemia Unmet Needs, KOL’s views, Analyst’s views, Beta Thalassemia Market Access and Reimbursement
Beta Thalassemia Market opportunities
- Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment
- The prevalence of thalassemia is expected to rise in the coming yearsü Alternative blood sources, such as paid donors or family members
- Improved national blood policies
- Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades
Table of Contents
1. Beta Thalassemia Market Report Introduction
2. Executive Summary for Beta Thalassemia
3. SWOT analysis of Beta Thalassemia
4. Beta Thalassemia Patient Share (%) Overview at a Glance
5. Beta Thalassemia Market Overview at a Glance
6. Beta Thalassemia Disease Background and Overview
7. Beta Thalassemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Beta Thalassemia
9. Beta Thalassemia Current Treatment and Medical Practices
10. Beta Thalassemia Unmet Needs
11. Beta Thalassemia Emerging Therapies
12. Beta Thalassemia Market Outlook
13. Country-Wise Beta Thalassemia Market Analysis (2019–2032)
14. Beta Thalassemia Market Access and Reimbursement of Therapies
15. Beta Thalassemia Market Drivers
16. Beta Thalassemia Market Barriers
17. Beta Thalassemia Appendix
18. Beta Thalassemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Beta Thalassemia treatment, visit @ Beta Thalassemia Medications
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis
